Plozasiran Cuts Pancreatitis Across Two Phase 3 Trials

Company Arrowhead Pharmaceuticals Event Type Clinical Trial Results (Phase 3) Modality RNA Interference (Liver-Targeted siRNA) Asset Plozasiran (TRiM Platform) Target APOC3 (Apolipoprotein C-III) Disease Area Severe Hypertriglyceridemia / Acute Pancreatitis Prevention Summary Arrowhead’s plozasiran met the primary endpoint and every prespecified secondary endpoint in the…